Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men

D. Front*, O. Israel, G. Iosilevsky, E. Even-Sapir, S. Ben-Haim, A. Frenkel, R. Ber, D. Milstein, G. M. Kolodny

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Tumor concentrations of the chemotherapeutic drug, bleomycin, labeled with cobalt-57 (Co-bleo) were compared in mouse tumor models and in human lung tumors using quantitative single-photon emission computed tomography. Drug concentrations in histologically similar human tumors showed marked variability for the same injected dose (ID). Small cell carcinomas showed concentrations between 1.09 and 8.85 %ID/cc x 10-3 while non-small cell lung tumors showed a concentration variation between 0.36 and 6.75 %ID/cc x 10-3. In contrast to the situation in human tumors, uptake in mouse tumors showed only slight variability in animals with the same tumor model. EMT-6 tumors in mice showed at 6 hr significantly higher uptake of Co-bleo (p < 0.001) and significantly higher tumor-to-lung ratio (p < 0.001) when compared to murine fibrosarcomas. The EMT-6 tumors in contrast to the fibrosarcomas responded to bleomycin treatment in a dose dependent manner. The results indicate that while in mice the tumor dose closely follows the administered dose, in humans, the tumor dose and the tumor-to-lung ratio in the individual patient cannot be predicted from the administered dose.

Original languageEnglish
Pages (from-to)1784-1790
Number of pages7
JournalJournal of Nuclear Medicine
Issue number11
StatePublished - 1990
Externally publishedYes


Dive into the research topics of 'Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men'. Together they form a unique fingerprint.

Cite this